Guggenheim Reiterates Buy Rating on Zevra Therapeutics
Guggenheim maintains a Buy rating on Zevra Therapeutics with a $29 price target.
Key Points
- Guggenheim reiterated its Buy rating on Zevra Therapeutics, setting a $29 price target as of June 10, 2026.
- Shares of Zevra Therapeutics (NasdaqGS: ZVRA) traded near $12.96, with a market cap of about $747.8 million and a P/E ratio of 6.29.
- Insiders have been active, with recent purchases by executives and analysts maintaining positive ratings with targets up to $35.
Guggenheim has reiterated its Buy rating on Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), maintaining a price target of $29. This update from analyst Eddie Hickman came on June 10, 2026, as the stock traded near $12.96.
Zevra Therapeutics Stock Snapshot
Shares of Zevra Therapeutics are trading around $12.96 on the NasdaqGS. The company has a market cap of approximately $747.8 million. It boasts a P/E ratio of 6.29 and a beta of 0.894, indicating lower volatility compared to the market. Over the past year, the stock has ranged from a low of $7.16 to a high of $14.27, with moving averages of $10.71 over 50 days and $9.52 over 200 days. The company maintains a healthy current ratio of 4.89 and a quick ratio of 4.736, with a debt-to-equity ratio of 0.557.
Recent Earnings
In its recent earnings, Zevra Therapeutics reported revenue of $122.3 million, reflecting a growth rate of 77.5%. The company achieved a net margin of 1.02% and a return on equity of 1.01%. Earnings per share stood at $2.01. The next earnings report is expected on May 6, 2026.
Insider Buying and Selling at Zevra Therapeutics, Inc.
Insider trading activity at Zevra Therapeutics includes several notable transactions. On May 28, 2026, Timothy Sangiovanni, SVP of Finance & Corporate Controller, purchased 40,000 shares. Rahsaan Thompson, Chief Legal & Compliance Officer, sold 1,794 shares on May 11, 2026, at an average price of $11.30 as part of a planned sale. Earlier in March, CFO Justin Renz acquired 300,000 shares.
Analysts Set New Price Targets
Several analysts have maintained their positive outlook on Zevra Therapeutics. On June 10, 2026, Maxim Group maintained a Buy rating with a $35 target, while Guggenheim reiterated its Buy rating with a $29 target. Canaccord Genuity also maintained a Buy rating with a $29 target on June 11, 2026. The consensus among nine analysts is a strong buy, with an average target price of $27.89.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. The company focuses on developing treatments for rare diseases using its Ligand Activated Technology platform. Its leading product candidates include KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers Danlos syndrome. Zevra also offers AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. The company is led by CEO Neil F. McFarlane and employs 61 people.
Bottom Line
Guggenheim's reiteration of a Buy rating on Zevra Therapeutics underscores confidence in the company's potential, with a price target of $29. Investors track these ratings closely, as they provide insight into the stock's perceived value. It's important to remember that analyst ratings are based on past and current data and may not reflect future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.